<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00146549</url>
  </required_header>
  <id_info>
    <org_study_id>01-087</org_study_id>
    <nct_id>NCT00146549</nct_id>
  </id_info>
  <brief_title>Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Randomized Phase III Study of Trastuzumab (Herceptin) in Combination With Either Vinorelbine (Navelbine), or Taxane-based Chemotherapy in Patients With HER2 Overexpressing Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Shore Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two different combinations of chemotherapy with&#xD;
      trastuzumab as initial treatment for HER2 positive advanced breast cancer. Half of the&#xD;
      patients will receive trastuzumab in combination with a taxane form of chemotherapy (either&#xD;
      paclitaxel or docetaxel), while the other group will receive trastuzumab in combination with&#xD;
      vinorelbine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  All patients will receive trastuzumab then be randomized into one of two arms. Arm A:&#xD;
           Trastuzumab in combination with weekly vinorelbine and Arm B: Trastuzumab in combination&#xD;
           with a weekly taxane-based regimen, either paclitaxel or docetaxel, chosen at the&#xD;
           discretion of the investigator.&#xD;
&#xD;
        -  Treatment is administered on an outpatient basis. Trastuzumab is administered weekly.&#xD;
           There is a one-time loading dose for the first week of the first cycle. For that initial&#xD;
           treatment, only, the trastuzumab dose is 4mg/kg. The dose for all subsequent weekly&#xD;
           trastuzumab treatments is 2mg/kg.&#xD;
&#xD;
        -  Arm A: vinorelbine is administered every week and the dose is adjusted based on the&#xD;
           absolute neutrophil count for that week. Vinorelbine is given after trastuzumab.&#xD;
&#xD;
        -  Arm B: Either paclitaxel given weekly (dose bases on absolute neutrophil count) or&#xD;
           docetaxel given on weeks 1,2,3,5,6,7 of each 8-week cycle (dose based upon absolute&#xD;
           neutrophil count). Patients on paclitaxel will also receive dexamethasone,&#xD;
           diphenhydramine and ranitidine to help prevent allergic or hypersensitivity reactions.&#xD;
           Patients on docetaxel will receive dexamethasone to help reduce fluid retention or&#xD;
           edema.&#xD;
&#xD;
        -  Every 8 weeks the patients cancer will be re-evaluated to see if the treatment is&#xD;
           working. If the treatment appears to be working, treatment will continue. Standard&#xD;
           radiological testing (x-rays, CT scan, radioactive drug scans, or MRI's) will be used to&#xD;
           follow the disease treatment.&#xD;
&#xD;
        -  Heart function will be measured after 16 weeks to be sure it is safe to continue&#xD;
           treatment.&#xD;
&#xD;
        -  Every 8 weeks, patients' will be asked to complete a brief written survey that asks&#xD;
           about symptoms and side effects.&#xD;
&#xD;
        -  Patients' will remain on the treatment as long as there is no disease progression or&#xD;
           unacceptable side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the overall response rate for patients receiving trastuzumab in combination with either vinorelbine or taxane-based chemotherapy.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization of the time to disease progression and time to treatment failure for patients receiving trastuzumab with either vinorelbine or taxane-based chemotherapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of side effects for both treatments</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>analysis of quality of life for patients receiving either treatment.</measure>
  </secondary_outcome>
  <enrollment>250</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed invasive breast cancer, with stage IV&#xD;
             disease&#xD;
&#xD;
          -  Tumors must be HER2 overexpressing&#xD;
&#xD;
          -  Measurable disease, defined as a least one lesion that can be accurately measured in&#xD;
             at least one dimension&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Life expectancy of greater than 6 months&#xD;
&#xD;
          -  ECOG performance status of 0-2&#xD;
&#xD;
          -  ANC count &gt; 1,500/mm3&#xD;
&#xD;
          -  Platelets &gt; 100,000/mm3&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 mg/dl&#xD;
&#xD;
          -  AST/ALT &lt; 115 U/I&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dl&#xD;
&#xD;
          -  Glucose &lt; 200 mg/dl&#xD;
&#xD;
          -  LVEF &gt; 50%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy or prior trastuzumab therapy for metastatic breast cancer&#xD;
&#xD;
          -  Concurrent hormonal therapy, chemotherapy, or radiation treatments&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Known brain metastases or leptomeningeal carcinomatosis&#xD;
&#xD;
          -  History of grade 3 or 4 allergic reactions attributed to compounds of similar chemical&#xD;
             or biologic composition to the agents in this study&#xD;
&#xD;
          -  Pre-existing neuropathy from any cause in excess of grade 1&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  History of other non-breast cancer malignancy except for carcinoma in situ of the&#xD;
             cervix or non-melanoma skin cancer&#xD;
&#xD;
          -  Patients taking macrolide antibiotics, ketoconazole, or AZT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold Burstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>October 30, 2009</last_update_submitted>
  <last_update_submitted_qc>October 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2009</last_update_posted>
  <keyword>HER2-positive Breast cancer</keyword>
  <keyword>HER2 overexpressing</keyword>
  <keyword>trastuzumab</keyword>
  <keyword>Herceptin</keyword>
  <keyword>vinorelbine</keyword>
  <keyword>Navelbine</keyword>
  <keyword>Taxotere</keyword>
  <keyword>taxol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

